A snapshot of subcutaneous infliximab uses in inflammatory rheumatic diseases: a multicentric Italian study
Therapeutic Advances in Musculoskeletal Disease
Published online on April 27, 2026
Abstract
Therapeutic Advances in Musculoskeletal Disease, Volume 18, January-December 2026.
Background:The recent availability of infliximab subcutaneous biosimilar in Europe represents a significant advancement in therapeutic delivery. Real-world data regarding the new formulation are still limited.Objectives:To describe subcutaneous infliximab ...
Background:The recent availability of infliximab subcutaneous biosimilar in Europe represents a significant advancement in therapeutic delivery. Real-world data regarding the new formulation are still limited.Objectives:To describe subcutaneous infliximab ...